Clinical Trial Update: A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 4 trial updates for SYR-472 in combination with insulin in type 2 diabetes; results posted and study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SYR-472

Snippet

Sponsor: Takeda | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2019-02-11